Alnylam Pharmaceuticals last week released data from a phase I study of its siRNA-based hypercholesterolemia drug ALN-PCS, reporting that a single dose of the agent could significantly and durably lower both its target and low-density lipoprotein cholesterol levels.

In the study, 32 healthy volunteers with elevated LDL were enrolled into six sequential dose cohorts, ranging from 0.015 mg/kg to 0.4 mg/kg. Patients were randomized to receive either drug or placebo.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

GNC will start using DNA testing to authentic the presence of plants included in its labels, following an agreement with the New York Attorney General.

Fareed Zakaria writes that instead of focusing solely on STEM-related courses, students would do well to pursue the liberal arts if they want to be technology innovators.

A Harvard Business Review study found four major patterns of gender biases and added that black and Latina scientists further had to navigate racial stereotypes.

In PLOS this week: variant linked to canine cleft lip, new compression tool, and more.